TARGAXAN Film-coated tablet Ref.[11130] Active ingredients: Rifaximin

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2021  Publisher: Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK

Product name and form

TARGAXAN 550 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Pink, oval biconvex 10 mm x 19 mm film-coated tablets embossed with “RX” on one side.

Qualitative and quantitative composition

Each film-coated tablet contains 550 mg rifaximin.

Excipients: For the full list of excipients, see section 6.1.

Active Ingredient Description
Rifaximin

Rifaximin is an antibacterial agent of the rifamycin class that inhibits bacterial RNA synthesis. Rifaximin has a broad antimicrobial spectrum against most of the Gram-positive and -negative, aerobic and anaerobic bacteria responsible for intestinal infections.

List of Excipients

Tablet core:

Sodium starch glycolate type A
Glycerol distearate
Colloidal anhydrous silica
Talc
Microcrystalline cellulose

Film coat (opadry oy-s-34907):

Hypromellose
Titanium dioxide (E171)
Disodium edetate
Propylene glycol
Red iron oxide (E172)

Pack sizes and marketing

PVC-PE-PVDC/Aluminium foil blisters in cartons of 14, 28, 42, 56 or 98 tablets.

Not all pack-sizes may be marketed.

Marketing authorization holder

Norgine Pharmaceuticals Limited, Norgine House, Widewater Place, Moorhall Road, Harefield, Uxbridge, UB9 6NS, UK

Marketing authorization dates and numbers

PL 20011/0020

10/01/2013

Drugs

Drug Countries
TARGAXAN Finland, Ireland, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.